Rhenman & Partners Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Rhenman & Partners Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,750	Closed	-$909K	–	93
2022 Q1	$909K	Hold	3,750	–	–	0.09%	88
2021 Q4	$1.18M	Hold	3,750	–	–	0.08%	89
2021 Q3	$1.55M	Hold	3,750	–	–	0.11%	88
2021 Q2	$1.15M	Hold	3,750	–	–	0.08%	93
2021 Q1	$771K	Hold	3,750	–	–	0.05%	92
2020 Q4	$750K	Hold	3,750	–	–	0.06%	83
2020 Q3	$621K	Hold	3,750	–	–	0.06%	79
2020 Q2	$930K	Hold	3,750	–	–	0.1%	81
2020 Q1	$684K	Hold	3,750	–	–	0.1%	80
2019 Q4	$1.09M	Hold	3,750	–	–	0.12%	81
2019 Q3	$1.02M	Hold	3,750	–	–	0.13%	78
2019 Q2	$1.41M	Hold	3,750	–	–	0.16%	74
2019 Q1	$1M	Hold	3,750	–	–	0.12%	73
2018 Q4	$798K	Hold	3,750	–	–	0.09%	72
2018 Q3	$1.68M	Hold	3,750	–	–	0.17%	68
2018 Q2	$1.52M	Hold	3,750	–	–	0.16%	71
2018 Q1	$2.05M	Buy	+3,750	New	+$2.32M	0.25%	68

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rhenman & Partners Asset Management's PVLA Position: Q2 2022 in Review

Rhenman & Partners Asset Management sold out of Palvella Therapeutics (PVLA) in Q2 2022, closing a stake of 3,750 shares — an estimated $909K sold.

Rhenman & Partners Asset Management first reported a position in PVLA in Q1 2018 and held it in 17 quarters. The position peaked at $2.05M in Q1 2018. 68 funds tracked by Wall St. Rank hold PVLA as of Q2 2022.

Rhenman & Partners Asset Management reported no remaining Palvella Therapeutics position as of Q2 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 3,750 Palvella Therapeutics shares in Q2 2022, an estimated $909K.
Rhenman & Partners Asset Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 17 quarters.
Rhenman & Partners Asset Management's Palvella Therapeutics position peaked at $2.05M in Q1 2018.
68 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.